30824180 30038413 34175327 31594920 29486374 36402243 31358468 35988792 29792024 35831706 32278058 33071070 35248529 - Search Results

Year	Number of Results
2018	3
2019	4
2020	2
2021	2
2022	4
2023	0

1

Neuropharmacological Insight from Allosteric Modulation of mGlu Receptors.

Stansley BJ, Conn PJ. Stansley BJ, et al. Trends Pharmacol Sci. 2019 Apr;40(4):240-252. doi: 10.1016/j.tips.2019.02.006. Epub 2019 Feb 26. Trends Pharmacol Sci. 2019. PMID: 30824180 Free PMC article. Review.

2

Chronic clozapine treatment restrains via HDAC2 the performance of mGlu2 receptor agonism in a rodent model of antipsychotic activity.

de la Fuente Revenga M, Ibi D, Cuddy T, Toneatti R, Kurita M, Ijaz MK, Miles MF, Wolstenholme JT, González-Maeso J. de la Fuente Revenga M, et al. Neuropsychopharmacology. 2019 Jan;44(2):443-454. doi: 10.1038/s41386-018-0143-4. Epub 2018 Jul 7. Neuropsychopharmacology. 2019. PMID: 30038413 Free PMC article.

3

Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders.

Dogra S, Conn PJ. Dogra S, et al. Neuropharmacology. 2021 Sep 15;196:108687. doi: 10.1016/j.neuropharm.2021.108687. Epub 2021 Jun 25. Neuropharmacology. 2021. PMID: 34175327 Free PMC article. Review.

4

Developing neuroscience-based treatments for alcohol addiction: A matter of choice?

Heilig M, Augier E, Pfarr S, Sommer WH. Heilig M, et al. Transl Psychiatry. 2019 Oct 8;9(1):255. doi: 10.1038/s41398-019-0591-6. Transl Psychiatry. 2019. PMID: 31594920 Free PMC article. Review.

5

The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia.

Stansley BJ, Conn PJ. Stansley BJ, et al. Curr Opin Pharmacol. 2018 Feb;38:31-36. doi: 10.1016/j.coph.2018.02.003. Epub 2018 Feb 24. Curr Opin Pharmacol. 2018. PMID: 29486374 Free PMC article. Review.

6

Metabotropic glutamate receptor 3 as a potential therapeutic target for psychiatric and neurological disorders.

Dogra S, Putnam J, Conn PJ. Dogra S, et al. Pharmacol Biochem Behav. 2022 Nov;221:173493. doi: 10.1016/j.pbb.2022.173493. Epub 2022 Nov 17. Pharmacol Biochem Behav. 2022. PMID: 36402243 Review.

7

Further exploration of an N-aryl phenoxyethoxy pyridinone-based series of mGlu₃ NAMs: Challenging SAR, enantiospecific activity and in vivo efficacy.

Yamada Y, Yohn SE, Gilliland K, Loch MT, Schulte ML, Rodriguez AL, Blobaum AL, Niswender CM, Conn PJ, Lindsley CW. Yamada Y, et al. Bioorg Med Chem Lett. 2019 Sep 15;29(18):2670-2674. doi: 10.1016/j.bmcl.2019.07.030. Epub 2019 Jul 19. Bioorg Med Chem Lett. 2019. PMID: 31358468

8

Advances in translating mGlu₂ and mGlu₃ receptor selective allosteric modulators as breakthrough treatments for affective disorders and alcohol use disorder.

Tyler RE, Besheer J, Joffe ME. Tyler RE, et al. Pharmacol Biochem Behav. 2022 Sep;219:173450. doi: 10.1016/j.pbb.2022.173450. Epub 2022 Aug 18. Pharmacol Biochem Behav. 2022. PMID: 35988792 Review.

9

Metabotropic Glutamate Receptors in Alcohol Use Disorder: Physiology, Plasticity, and Promising Pharmacotherapies.

Joffe ME, Centanni SW, Jaramillo AA, Winder DG, Conn PJ. Joffe ME, et al. ACS Chem Neurosci. 2018 Sep 19;9(9):2188-2204. doi: 10.1021/acschemneuro.8b00200. Epub 2018 Jun 8. ACS Chem Neurosci. 2018. PMID: 29792024 Free PMC article.

10

Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia.

Veselinović T, Neuner I. Veselinović T, et al. CNS Drugs. 2022 Aug;36(8):819-858. doi: 10.1007/s40263-022-00935-z. Epub 2022 Jul 13. CNS Drugs. 2022. PMID: 35831706 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results